Sumoson, Riza H.
HRN: 04-91-15 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
07/16/2024
CO-AMOXICLAV 625MG (TAB)
07/16/2024
07/23/2024
ORAL
625mg
BID
NSVD Post Episioraphy
Waiting Final Action
Indication: Empiric Type of Infection: Reproductive Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes